Merck & Co/MSD has agreed to buy Pandion for $1.85 billion, bolting on a pipeline of drugs for autoimmune and other immunological disorders headed by interleukin-2 (IL-2) based therapy PT-101.

This study confirms that TEV-56278 targets IL-2 activity to PD-1 expressing T cells within the tumor microenvironment and induces strong immune response, thereby promoting anti-tumor activity.

A Phase 1/2 clinical study of PD-1/IL-2 α-bia s bispecific antibody fusion protein (IBI363) in the treatment of advanced "cold" tumor subtypes (acral and mucosal) malignant melanoma. The data ...

The purpose of this study is to develop a TIL cell therapy product (HS-IT101) that requires low-dose lymphodepletion and IL-2 infusion to reduce safety risks and to improve clinical accessibility.

Interleukin-2 (IL-2) is a pivotal cytokine that plays a crucial role in the activation, proliferation, and functional regulation of multiple immune cells. High-dose IL-2 has been approved for ...

Next year's iPhone 18 will use TSMC's next-generation 2-nanometer fabrication process in combination with an advanced new ...

M3GAN stands for “Model 3 Generative ANdroid.” She was created by programmer Gemma (Allison Williams, reprising her role here ...

This would allow for, say, the A20’s RAM to be integrated with the CPU, GPU, Neural Engine, and other wafer-level components. This is different from the current method of using a silicon ...

All in all, the A20 chip is shaping up to be a big upgrade for the iPhone 18 Pro and iPhone 18 Fold models, which should launch in September 2026. Related Roundup: iPhone 18. Tag: Jeff Pu.

Apple’s upcoming A20 chip is rumored to be exclusive to the iPhone 18 Pro, Pro Max, and the company’s first foldable phone, marking a major performance leap with TSMC’s 2nm process.

Sources familiar with the matter tell the Commercial Times that production of the A20 SoC will begin at the Chiayi AP7 plant in Taiwan. The current ...